Rare Disease Genetic Testing Market Report 2026

The rare disease genetic testing market size has grown rapidly in recent years. It will grow from $1.17 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to improvements in genomic sequencing technologies, expansion of rare disease research initiatives, rising awareness of genetic disorders, availability of specialized diagnostic laboratories, growth in clinical genetics programs.

The rare disease genetic testing market size is expected to see rapid growth in the next few years. It will grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising investments in genomic data analytics, expansion of population-scale genetic screening, growing integration of genetics into routine clinical care, advancements in bioinformatics platforms. Major trends in the forecast period include increasing adoption of next-generation sequencing for rare diseases, growing use of AI-driven variant interpretation, expansion of comprehensive genetic testing panels, rising integration of genetic data with clinical decision systems, enhanced focus on early and accurate diagnosis.

The increasing prevalence of genetic disorders is expected to drive the growth of the rare disease genetic testing market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual’s deoxyribonucleic acid, which can be inherited from one or both parents or result from new mutations. The rise in genetic disorders is partly due to increasing parental age, as older parents have a higher likelihood of passing genetic mutations to their children. Rare disease genetic testing enables the identification of specific mutations, supporting accurate and early diagnosis. It also facilitates personalized treatment planning, improving patient care and long-term health outcomes. For example, in May 2024, the National Health Service in the UK reported that 17,000 people were living with sickle cell disease, an inherited genetic blood disorder, with approximately 250 new cases diagnosed annually. Thus, the growing incidence of genetic disorders is fueling the expansion of the rare disease genetic testing market.

Leading companies in the rare disease genetic testing market are increasingly developing technologically advanced solutions, such as digital genomics platforms, to improve the speed, accuracy, and scalability of rare disease diagnosis. Digital genomics platforms are sophisticated software systems that integrate genomic data analysis, interpretation, and reporting, streamlining and accelerating genetic testing processes. For instance, in March 2025, Strand Life Sciences Private Limited, an India-based software company, launched the StrandOmics Portal, a digital platform designed to enhance the efficiency and precision of rare disease diagnosis. The portal provides clinicians with detailed insights into genetic variants, enabling faster and more accurate diagnoses. It also supports advanced variant interpretation, including prenatal diagnostics, and allows independent review of genetic data. This launch highlights a strong focus on advancing precision medicine and equipping healthcare professionals with effective tools to improve patient outcomes.

In August 2024, Labcorp, a US-based provider of laboratory diagnostics and life sciences services, acquired selected assets of Invitae for an undisclosed amount. This acquisition allows Labcorp to expand its genetic testing capabilities by integrating Invitae’s advanced technologies for oncology and certain rare diseases, offering more comprehensive genomic insights to aid diagnosis, treatment decisions, and personalized patient care. Invitae Corporation is a US-based company specializing in medical and hereditary genetic testing across a wide range of inherited and rare conditions.

Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., Genomics England Ltd.

North America was the largest region in the rare disease genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare disease genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the rare disease genetic testing market by increasing costs of imported sequencing instruments, reagents, laboratory consumables, and bioinformatics hardware. Diagnostic laboratories and research institutions in North America and Europe are most affected due to dependence on imported high-precision equipment, while Asia-Pacific faces higher costs for test kit manufacturing. These tariffs are raising testing prices and extending adoption timelines. At the same time, they are encouraging local reagent production, regional laboratory expansion, and development of cost-optimized genetic testing solutions.

The rare disease genetic testing market research report is one of a series of new reports that provides rare disease genetic testing market statistics, including rare disease genetic testing industry global market size, regional shares, competitors with a rare disease genetic testing market share, detailed rare disease genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease genetic testing industry. This rare disease genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rare disease genetic testing involves analyzing an individual’s DNA to detect genetic mutations or variations that may cause or contribute to a rare disease. This testing supports accurate diagnosis, early intervention, and personalized treatment planning for patients with rare or undiagnosed conditions.

The primary disease categories in rare disease genetic testing include immunological disorders, cardiovascular disorders, neurological diseases, endocrine and metabolic disorders, hematological diseases, dermatological diseases, and others. Immunological disorders are conditions in which the immune system functions abnormally, either by overreacting, underreacting, or attacking the body’s own tissues. These disorders are identified using various technologies, including next-generation sequencing, Sanger sequencing, polymerase chain reaction (PCR)-based testing, array-based testing, fluorescence in situ hybridization (FISH), and more. Regarding specialty testing, it is divided into molecular genetic tests, chromosomal genetic tests, and biochemical genetic tests. These tests serve a broad range of end users, such as hospitals and clinics, research laboratories and contract research organizations, diagnostic laboratories, and other relevant users.

The rare disease genetic testing market consists of revenues earned by entities by providing services such as whole exome sequencing, targeted gene panel testing, whole genome sequencing, carrier screening, and newborn genetic screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare disease genetic testing market also includes sales of genetic testing kits, bioinformatics software, next-generation sequencing (NGS) platforms, laboratory reagents and consumables, and targeted gene panels. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.